Pfizer's Vyndaqel approved in European Union

Pfizer announced that their drug, Vyndaqel, has been approved by the European Commission. The drug was created to treat Transthyretin Familial Amyloid Polyneuropathy (a neurodegenerative disease) in adult patients with stage 1 symptomatic polyneuropathy. Approval of the treatment came as a result of the successful clinical trial to test the efficacy and long term safety of Vyndaqel. Along with delaying peripheral neurologic impairment, the study showed that the drug was effective in reducing deterioration in neurological function, large fiber function, and small fiber function by 51 to 81 percent. The European Union and Pfizer are working closely with European health authorities to make the drug available for market by 2012.


SOURCE: Pfizer Press Release